A delayed hypersensitivity reaction to enfuvirtide after rechallenge

International Journal of STD and AIDS

Volumn 20, Issue 4, 2009, Pages 288-289

  Emerson, C R ^a,b,e   Post, J J ^a,b,c   Workman, C ^d  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d AIDS Research Initiative   (Australia)

^e ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

Enfuvirtide; HIV; Hypersensitivity

Indexed keywords

ABACAVIR; AMPRENAVIR; COTRIMOXAZOLE; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; ETRAVIRINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; RALTEGRAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ABDOMEN; ADULT; ARTICLE; CASE REPORT; DELAYED HYPERSENSITIVITY; DRUG SELF ADMINISTRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEVER; HEMODYNAMICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACULOPAPULAR RASH; MALE; NAUSEA; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS; RASH; RETREATMENT; SYNCOPE; TEMPERATURE; THORAX;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG HYPERSENSITIVITY; EXANTHEMA; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; HYPERSENSITIVITY, DELAYED; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS;

EID: 66349089692     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2008.008331     Document Type: Article

References (9)

1. Clotet B, Raffi F, Cooper D, et al. Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations. AIDS 2004;18:1137-1146
2. Roujeau J-C, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331:1272-1285 (Pubitemid 24333193)
3. Coopman MA, Johnson RA, Platt R, Stern RS. Cutaneous disease and drug reactions in HIV infection. N Engl J Med 1993;328:1670-1674 (Pubitemid 23157349)
4. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1 infected patients in DUET-2:24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370:39-48 (Pubitemid 47017467)
5. Squires K, Pozniak AL, Pierone G, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1. Ann Intern Med 2003;139:313-320
6. Dwyer DE, Workman C, Hales G, et al. Enfuvirtide in HIV-1 infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: the ALLIANCE study. Antivir Ther 2006;11:409-419 (Pubitemid 44024848)
7. DeSimone JA, Ojha A, Pathak R, Cohn J. Successful desensitisation to enfuvirtide after a hypersensitivity reaction in an HIV-1 infected man. Clin Infect Dis 2004;39:e110-2
8. Machado ES, Passoni LFC, Sidi LC, Andrade HB, De Menezes JA. Successful desensitisation of enfuvirtide after a first attempt failure (correspondence). AIDS 2006;20:2130-2131 (Pubitemid 44611072)
9. Eduardo S, Moar C, Shimon P. Successful desensitisation of enfuvirtide-induced skin hypersensitivity reaction (correspondence). AIDS 2005;19:451-452 (Pubitemid 40446196)